Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Combination With Chemotherapy in Patients With Metastatic or Recurrent Squamous Cell Head and Neck Carcinoma.

Trial Profile

Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Combination With Chemotherapy in Patients With Metastatic or Recurrent Squamous Cell Head and Neck Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2009

At a glance

  • Drugs Cetuximab; Cisplatin; Fluorouracil; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2009 ImClone Systems added as trial affiliate and sponsor as reported by ClinicalTrials.gov.
    • 20 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top